Rivaroxaban 2.5 mg
H-REPLACE-201711
Approved small_molecule completed
Quick answer
Rivaroxaban 2.5 mg for Acute Coronary Syndrome is a Approved program (small_molecule) at Second Xiangya Hospital of Central South University with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Second Xiangya Hospital of Central South University
- Indication
- Acute Coronary Syndrome
- Phase
- Approved
- Modality
- small_molecule
- Status
- completed